Kura Oncology, Inc. (KURA) is a publicly traded Healthcare sector company. As of May 21, 2026, KURA trades at $10.27 with a market cap of $816.72M and a P/E ratio of -3.19. KURA moved +15.29% today. Year to date, KURA is +8.39%; over the trailing twelve months it is +62.07%. Its 52-week range spans $5.41 to $19.94. Analyst consensus is strong buy with an average price target of $28.13. Rallies surfaces KURA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies organizes KURA SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
| Metric | Value |
|---|---|
| Price | $10.27 |
| Market Cap | $816.72M |
| P/E Ratio | -3.19 |
| EPS | $-3.18 |
| Dividend Yield | 0.00% |
| 52-Week High | $19.94 |
| 52-Week Low | $5.41 |
| Volume | 11.20K |
| Avg Volume | 0 |
| Revenue (TTM) | $67.48M |
| Net Income | $-278.67M |
| Gross Margin | 0.00% |
10 analysts cover KURA: 0 strong buy, 9 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $28.13.